Call for Abstract

2nd International Conference and Exhibition on In Silico Drug Designing & QSAR, will be organized around the theme “In Silico Drug Designing Strategies and Approaches ”

Drug Designing-2013 is comprised of 9 tracks and 47 sessions designed to offer comprehensive sessions that address current issues in Drug Designing-2013.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Target discovery
  • Track 1-2Drug discovery
  • Track 1-3Safety and drug metabolism
  • Track 1-4Clinical trials
  • Track 1-5Registration and pharmacovigilance
  • Track 2-1Systems dynamics
  • Track 2-2Computational approaches to dynamic systems
  • Track 2-3Medical and microbial systems biology
  • Track 2-4Metabolic engineering
  • Track 2-5Genome design
  • Track 2-6Next generation tools for systems biology
  • Track 3-1Translation of animal models to the clinic
  • Track 3-2Biomarkers in translational medicine
  • Track 3-3Developing predictive preclinical models
  • Track 3-4Translational modelling of efficacy & safety
  • Track 4-1Pharmacophore modelling in drug design
  • Track 4-2Introduction to population pharmacokinetics
  • Track 4-3Multicompartment kinetics
  • Track 4-4New tools & methods in PK/PD
  • Track 4-5Pharmacokinetics and pharmacodynamics modelling
  • Track 4-6Application of pharmacokinetics in clinical practice
  • Track 5-1CADD in protein therapeutics
  • Track 5-2Computational approaches to polypharmacology
  • Track 5-3Structure-based drug design to identify novel oral & inhaled p38 inhibitors for copd
  • Track 5-4Drug binding and subtype selectivity in g-protein-coupled receptors
  • Track 6-1Molecular modelling and simulation
  • Track 6-2Novel drugable targets: Identification and selection
  • Track 6-3Fragment binding and selectivity
  • Track 6-4Structure-based inhibitor design
  • Track 6-5Ligand design and identification
  • Track 6-6Target-ligand interaction (including proteins and nucleic acids)
  • Track 6-7In silico and experimental screening technologies
  • Track 7-1Docking approaches and tools involved
  • Track 7-2Virtual screening techniques and docking
  • Track 7-3Scoring methods
  • Track 7-4Parameters influencing the docking results
  • Track 8-1QSAR techniques applied to 5HT3 receptor antagonists
  • Track 8-2QSAR in the real world
  • Track 8-3New techniques in lead optimisation by Qsar
  • Track 8-4Neural networks in qsar: Uses and abuses
  • Track 8-5Problems and pitfalls in Qsar
  • Track 9-1ADME and metabolomics
  • Track 9-2ADME optimisation for drug design/discovery
  • Track 9-3Genotoxicity and toxicokinetic modeling
  • Track 9-4New therapeutic targets in drug design/discovery
  • Track 9-5Pharmacogenomics and drug safety
  • Track 9-6Regulatory Issues in ADME